Iacopo Olivotto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8019781/publications.pdf

Version: 2024-02-01

337 papers	22,938 citations	13099 68 h-index	9861 141 g-index
367 all docs	367 docs citations	367 times ranked	12893 citing authors

#	Article	IF	Citations
1	Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. Heart, 2022, 108, 54-60.	2.9	12
2	The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2022, 29, 645-653.	1.8	20
3	Is heart failure with preserved ejection fraction a â€˜dementiaâ€™ of the heart?. Heart Failure Reviews, 2022, 27, 587-594.	3.9	7
4	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization â€” the first insight from the AC-TIVE Study. European Journal of Preventive Cardiology, 2022, 29, e173-e177.	1.8	21
5	External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2022, 29, 678-686.	1.8	30
6	Neither Athletic Training nor Detraining Affects LV Hypertrophy in Adult, Low-RiskÂPatients With HCM. JACC: Cardiovascular Imaging, 2022, 15, 170-171.	5.3	6
7	Creatine deficiency and heart failure. Heart Failure Reviews, 2022, 27, 1605-1616.	3.9	13
8	The Inglorious Art. JAMA Cardiology, 2022, 7, 127.	6.1	0
9	Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis. International Journal of Cardiology, 2022, 351, 71-77.	1.7	11
10	Sudden cardiac death in cardiomyopathies: acting upon â€œacceptableâ€•risk in the personalized medicine era. Heart Failure Reviews, 2022, 27, 1749-1759.	3.9	2
11	Strength of clinical indication and therapeutic impact of the implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2022, 353, 62-67.	1.7	2
12	Evaluation of stress myocardial blood flow patterns in patients with apical hypertrophic cardiomyopathy. Journal of Nuclear Cardiology, 2022, 29, 1946-1951.	2.1	3
13	Disease Progression of Hypertrophic Cardiomyopathy: Modeling Using Machine Learning. JMIR Medical Informatics, 2022, 10, e30483.	2.6	5
14	Gender Related Differences in the Clinical Presentation of Hypertrophic Cardiomyopathyâ€”An Analysis from the SILICOFCM Database. Medicina (Lithuania), 2022, 58, 314.	2.0	10
15	Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis. International Journal of Cardiology, 2022, 357, 88-94.	1.7	17
16	Diagnosis and Management of Rare Cardiomyopathies in Adult and Paediatric Patients. A Position Paper of the Italian Society of Cardiology (SIC) and Italian Society of Paediatric Cardiology (SICP). International Journal of Cardiology, 2022, 357, 55-71.	1.7	36
17	Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study. European Journal of Internal Medicine, 2022, 97, 36-41.	2.2	58
18	Sex related differences in exercise performance in patients with hypertrophic cardiomyopathy: Hemodynamic insights through non-invasive pressure volume analysis. International Journal of Cardiology, 2022, 351, 78-83.	1.7	2

#	Article	IF	Citations
19	Metabolomics Fingerprint Predicts Risk of Death in Dilated Cardiomyopathy and Heart Failure. Frontiers in Cardiovascular Medicine, 2022, 9, 851905.	2.4	3
20	Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis. Journal of Cardiac Failure, 2022, 28, 950-959.	1.7	8
21	Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different TNNT2 Mutations. Frontiers in Physiology, 2022, 13, 864547.	2.8	5
22	Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the <scp>ACâ€TIVE</scp> study, an <scp>Italian nationwide survey</scp>. European Journal of Heart Failure, 2022, 24, 1377-1386.	7.1	43
23	Sexâ€Related Differences in Genetic Cardiomyopathies. Journal of the American Heart Association, 2022, 11, e024947.	3.7	18
24	Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010075.	4.8	8
25	Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter. Journal of the American Heart Association, 2022, 11, e024656.	3.7	18
26	Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond. European Journal of Internal Medicine, 2022, 102, 1-7.	2.2	5
27	Clinical Features and Natural History of Preadolescent Nonsyndromic HypertrophicÂCardiomyopathy. Journal of the American College of Cardiology, 2022, 79, 1986-1997.	2.8	20
28	Impact of SARSâ€Covâ€2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Failure, 2022, 9, 2189-2198.	3.1	6
29	Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument. PharmacoEconomics - Open, 2022, 6, 563-574.	1.8	4
30	Bayesian Inference-Based Gaussian Mixture Models With Optimal Components Estimation Towards Large-Scale Synthetic Data Generation for In Silico Clinical Trials. IEEE Open Journal of Engineering in Medicine and Biology, 2022, 3, 108-114.	2.3	1
31	Sudden death in young athletes: Is it preventable?. European Journal of Internal Medicine, 2022, 104, 13-20.	2.2	3
32	Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside. Drugs, 2022, 82, 889-912.	10.9	18
33	Exercise-induced pulmonary hypertension in hypertrophic cardiomyopathy: a combined cardiopulmonary exercise testâ€"echocardiographic study. International Journal of Cardiovascular Imaging, 2022, 38, 2345-2352.	0.6	5
34	Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003062.	3.6	38
35	Prescribing, dosing and titrating exercise in patients with hypertrophic cardiomyopathy for prevention of comorbidities: Ready for prime time. European Journal of Preventive Cardiology, 2021, 28, 1093-1099.	1.8	15
36	Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions. Genetics in Medicine, 2021, 23, 69-79.	2.4	39

#	Article	IF	Citations
37	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. ESC Heart Failure, 2021, 8, 95-105.	3.1	23
38	Use of Smartphone-operated ECG for home ECG surveillance in COVID-19 patients. European Heart Journal Digital Health, 2021, 2, 175-178.	1.7	8
39	Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Longâ€term results and clinical outcomes. Journal of Cardiovascular Electrophysiology, 2021, 32, 657-666.	1.7	14
40	Predictors of mortality and adverse events in patients with infective endocarditis: a retrospective real world study in a surgical centre. BMC Cardiovascular Disorders, 2021, 21, 28.	1.7	15
41	The labyrinth of nomenclature in Cardiology. Eternal dilemmas and new challenges on the horizon in the personalized medicine era. European Journal of Heart Failure, 2021, 23, 1062-1067.	7.1	2
42	Mavacamten for hypertrophic obstructive cardiomyopathy â€“ Authors' reply. Lancet, The, 2021, 397, 369-370.	13.7	2
43	Potential resistance to SARS-CoV-2 infection in lysosomal storage disorders. CKJ: Clinical Kidney Journal, 2021, 14, 1488-1490.	2.9	3
44	Clinical and Laboratory Follow-up After Hospitalization for COVID-19 at an Italian Tertiary Care Center. Open Forum Infectious Diseases, 2021, 8, ofab049.	0.9	12
45	Cardiac Involvement in Fabry Disease. Journal of the American College of Cardiology, 2021, 77, 922-936.	2.8	109
46	Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 211-212.	3.0	9
47	Cardiogenic Shock in Obstructive Hypertrophic Cardiomyopathy Plus Apical Ballooning. JACC: Case Reports, 2021, 3, 433-437.	0.6	4
48	Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 Medicine, 2021, 85, 68-79.	2.2	14
49	Emerging Medical Treatment for Hypertrophic Cardiomyopathy. Journal of Clinical Medicine, 2021, 10, 951.	2.4	18
50	Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 1988-1996.	2.2	69
51	Prognostic Value of Reduced Heart Rate Reserve during Exercise in Hypertrophic Cardiomyopathy. Journal of Clinical Medicine, 2021, 10, 1347.	2.4	6
52	Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. Genetics in Medicine, 2021, 23, 1281-1287.	2.4	11
53	Ventricular tachyarrhythmias and sudden cardiac death in lightâ€chain amyloidosis: a clash of cardioâ€toxicities?. British Journal of Haematology, 2021, 193, e27-e31.	2.5	5
54	Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy. Heart Failure Clinics, 2021, 17, 303-313.	2.1	18

#	Article	IF	Citations
55	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss syndrome). European Respiratory Journal, 2021, 57, 2004158.	6.7	19
56	Endocarditis with spondylodiscitis: clinical characteristics and prognosis. BMC Cardiovascular Disorders, 2021, 21, 186.	1.7	3
57	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2021, 397, 2467-2475.	13.7	98
58	Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. Current Cardiology Reports, 2021, 23, 79.	2.9	17
59	1â€…The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy. , 2021, , .		2
60	Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. Current Heart Failure Reports, 2021, 18, 169-179.	3.3	19
61	Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy. JACC: Cardiovascular Imaging, 2021, 14, 2123-2134.	5.3	18
62	Age-dependent diagnostic yield of echocardiography as a second-line diagnostic investigation in athletes with abnormalities at preparticipation screening. Journal of Cardiovascular Medicine, 2021, 22, 759-766.	1.5	2
63	Arrhythmogenic potential of myocardial disarray in hypertrophic cardiomyopathy: genetic basis, functional consequences and relation to sudden cardiac death. Europace, 2021, 23, 985-995.	1.7	11
64	A computational pipeline for data augmentation towards the improvement of disease classification and risk stratification models: A case study in two clinical domains. Computers in Biology and Medicine, 2021, 134, 104520.	7.0	10
65	Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy. Clinical and Translational Medicine, 2021, 11, e435.	4.0	2
66	Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany. International Journal of Cardiology, 2021, 335, 123-127.	1.7	21
67	Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy. JAMA Oncology, 2021, 7, 1544.	7.1	35
68	Predicting Mortality Risk in Older Hospitalized Persons With COVID-19: A Comparison of the COVID-19 Mortality Risk Score with Frailty and Disability. Journal of the American Medical Directors Association, 2021, 22, 1588-1592.e1.	2.5	16
69	Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 2185-2191.	3.0	10
70	A machine learning-based risk stratification model for ventricular tachycardia and heart failure in hypertrophic cardiomyopathy. Computers in Biology and Medicine, 2021, 135, 104648.	7.0	27
71	Stress Echo 2030: The Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging. Journal of Clinical Medicine, 2021, 10, 3641.	2.4	33
72	Recognition of pre-hypertrophic cardiac involvement in Fabry Disease based on automated electrocardiographic measures. International Journal of Cardiology, 2021, 338, 121-126.	1.7	3

#	Article	IF	Citations
73	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 3932-3944.	2.2	43
74	Sex-related differences in ventricular remodeling after myocardial infarction. International Journal of Cardiology, 2021, 339, 62-69.	1.7	11
75	Clinical presentation and longâ€term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study. ESC Heart Failure, 2021, 8, 5057-5067.	3.1	22
76	Anti-arrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: The importance of optimal beta-blocker dose titration. International Journal of Cardiology, 2021, 338, 150-151.	1.7	1
77	Feasibility of a Combined Mobile-Health Electrocardiographic and Rapid Diagnostic Test Screening for Chagas-Related Cardiac Alterations. Microorganisms, 2021, 9, 1889.	3.6	4
78	Systematic large-scale assessment of the genetic architecture of left ventricular noncompaction reveals diverse etiologies. Genetics in Medicine, 2021, 23, 856-864.	2.4	45
79	The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review. Journal of Clinical Medicine, 2021, 10, 416.	2.4	3
80	Mavacamten â€" a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy. Kardiologia Polska, 2021, 79, 949-954.	0.6	5
81	Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2021, 10, e021141.	3.7	9
82	Sport practice in hypertrophic cardiomyopathy: running to stand still?. International Journal of Cardiology, 2021, 345, 77-82.	1.7	12
83	The Influence of Genotype on the Phenotype, Clinical Course, and Risk of Adverse Events in Children with Hypertrophic Cardiomyopathy. Heart Failure Clinics, 2021, 18, 1-8.	2.1	1
84	Myocardial blood flow in patients with hypertrophic cardiomyopathy receiving perindopril (CARAPaCE): a pilot study. Journal of Cardiovascular Medicine, 2021, 22, 511-513.	1.5	5
85	Prevalence of Inherited Cardiac Diseases Among Young Patients Requiring Permanent Pacing. Circulation: Arrhythmia and Electrophysiology, 2021, 14, CIRCEP121010562.	4.8	6
86	465â€ƒUnmasking the prevalence of cardiac amyloidosis in the real world: first insights from the phase 2 of active study, an Italian nationwide survey. European Heart Journal Supplements, 2021, 23, .	0.1	0
87	Variational Gaussian Mixture Models with robust Dirichlet concentration priors for virtual population generation in hypertrophic cardiomyopathy: a comparison study. , 2021, 2021, 1674-1677.		3
88	Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 2518-2532.	2.8	59
89	Implantable cardioverter-defibrillators for hypertrophic cardiomyopathy: The Times They Are a-Changinâ€™. Europace, 2021, , .	1.7	7
90	The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. Heart Rhythm, 2020, 17, 142-151.	0.7	65

#	Article	IF	Citations
91	Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. International Journal of Cardiology, 2020, 300, 191-195.	1.7	60
92	Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy. JAMA Cardiology, 2020, 5, 65.	6.1	78
93	Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2020, 27, 1821-1831.	1.8	15
94	Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team. International Journal of Cardiology, 2020, 304, 86-92.	1.7	29
95	IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASE. Retina, 2020, 40, 1623-1629.	1.7	4
96	Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. JAMA Cardiology, 2020, 5, 83.	6.1	60
97	Generation of virtual patient data for in-silico cardiomyopathies drug development using tree ensembles: a comparative study. , 2020, 2020, 5343-5346.		6
98	Electromechanical dissociation of left atrium in patients with Cardiac Amyloidosis by Magnetic Resonance: Prognostic and clinical correlates. IJC Heart and Vasculature, 2020, 31, 100633.	1.1	10
99	Impact of cardiovascular involvement on the clinical course of paediatric mitochondrial disorders. Orphanet Journal of Rare Diseases, 2020, 15, 196.	2.7	8
100	Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations. PLoS ONE, 2020, 15, e0236814.	2.5	1
101	Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2020, 318, 94-100.	1.7	15
102	Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Molecular Genetics and Metabolism, 2020, 131, 219-228.	1.1	44
103	Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2020, 13, e007230.	3.9	48
104	Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, 396-405.	3.6	47
105	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	13.7	481
106	Coronary microvascular function is impaired in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. European Journal of Neurology, 2020, 28, 3809-3813.	3.3	9
107	A rare case of pediatric cardiomyopathy: AlstrÃ¶m syndrome identified by gene panel analysis. Clinical Case Reports (discontinued), 2020, 8, 3369-3373.	0.5	2
108	Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy. BMC Cardiovascular Disorders, 2020, 20, 516.	1.7	33

#	Article	IF	Citations
109	Clinical Profile of Cardiac Involvement in Danon Disease. Circulation Genomic and Precision Medicine, 2020, 13, e003117.	3.6	29
110	Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy. Cardiovascular Research, 2020, 116, 1585-1599.	3.8	40
111	A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. Circulation, 2020, 142, 217-229.	1.6	129
112	Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy. Frontiers in Physiology, 2020, 11, 368.	2.8	9
113	Antiarrhythmic efficacy of anakinra in a young patient with autoimmune lymphocytic myocarditis. Rheumatology, 2020, 59, e88-e90.	1.9	8
114	Mitochondrial Energetics and Ca2+-Activated ATPase in Obstructive Hypertrophic Cardiomyopathy. Journal of Clinical Medicine, 2020, 9, 1799.	2.4	4
115	Study Design and Rationale of EXPLORER-HCM. Circulation: Heart Failure, 2020, 13, e006853.	3.9	48
116	Atrial Dysfunction Assessed by Cardiac Magnetic Resonance as an Early Marker of Fabry Cardiomyopathy. JACC: Cardiovascular Imaging, 2020, 13, 2262-2264.	5.3	20
117	The eighth alternative to evidence based medicine in the early era of the COVID-19 pandemic: Too much emergency and emotion, too little evidence. European Journal of Internal Medicine, 2020, 77, 163-164.	2.2	2
118	Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. Circulation: Heart Failure, 2020, 13, e006619.	3.9	31
119	Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy. Clinical Cardiology, 2020, 43, 430-440.	1.8	15
120	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. European Journal of Heart Failure, 2020, 22, 1076-1096.	7.1	96
121	The Importance of Sex Differences in Patients With Hypertrophic Cardiomyopathy â€“ Tailoring Management and Future Perspectives. American Journal of the Medical Sciences, 2020, 360, 433-434.	1.1	4
122	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. Journal of the American College of Cardiology, 2020, 76, 186-197.	2.8	45
123	Advantages and Perils of Clinical Whole-Exome and Whole-Genome Sequencing in Cardiomyopathy. Cardiovascular Drugs and Therapy, 2020, 34, 241-253.	2.6	21
124	Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study. Heart Rhythm, 2020, 17, 1107-1114.	0.7	26
125	Reevaluating the Genetic Contribution of Monogenic Dilated Cardiomyopathy. Circulation, 2020, 141, 387-398.	1.6	148
126	Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. Circulation, 2020, 141, 828-842.	1.6	181

#	Article	IF	Citations
127	Embolic risk stratification and prognostic impact of early surgery in left-sided infective endocarditis. European Journal of Internal Medicine, 2020, 78, 82-87.	2.2	13
128	The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy. European Journal of Heart Failure, 2020, 22, 1097-1107.	7.1	52
129	Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?. Journal of the American Heart Association, 2020, 9, e015473.	3.7	42
130	Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction. Circulation, 2020, 141, 1371-1383.	1.6	108
131	Targeted Medical Therapies for Hypertrophic Cardiomyopathy. Current Cardiology Reports, 2020, 22, 10.	2.9	12
132	On the Cardiac Loop and Its Failing: Left Ventricular Outflow Tract Obstruction. Journal of the American Heart Association, 2020, 9, e014857.	3.7	7
133	Feasibility and outcome of mitral valve repair in patients with infective endocarditis. The Cardiothoracic Surgeon, 2020, 28, .	0.5	2
134	The coronary microcirculation in sepsis: not of micro-importance. Global Cardiology Science & Practice, 2020, 2020, e202030.	0.4	1
135	Epidemiology of cardiomyopathies: essential context knowledge for a tailored clinical work-up. European Journal of Preventive Cardiology, 2020, , .	1.8	3
136	Abstract 16333: Racial Differences in Pressure-volume Relationships in Val122Ile Associated Cardiac Amyloidosis. Circulation, 2020, 142, .	1.6	0
137	Abstract 15391: The Natural History of Asymptomatic and Mildly Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the Share Registry. Circulation, 2020, 142, .	1.6	0
138	Abstract 14117: Clinical Characteristics and Cardiovascular Outcomes in Childhood-Onset Hypertrophic Cardiomyopathy. Circulation, 2020, 142, .	1.6	0
139	Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. Genetics in Medicine, 2019, 21, 284-292.	2.4	54
140	Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). JAMA Cardiology, 2019, 4, 918.	6.1	147
141	The spectrum of myocarditis: from pathology to the clinics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 279-301.	2.8	73
142	Heritability in genetic heart disease: the role of genetic background. Open Heart, 2019, 6, e000929.	2.3	17
143	Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy. JACC Basic To Translational Science, 2019, 4, 795-813.	4.1	35
144	Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. Journal of the American College of Cardiology, 2019, 74, 2333-2345.	2.8	152

#	Article	IF	Citations
145	Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. Genome Medicine, 2019, 11, 5.	8.2	90
146	Performance of the CHA2DS2-VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia. European Journal of Internal Medicine, 2019, 62, 24-28.	2.2	15
147	Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. Circulation, 2019, 139, 830-833.	1.6	43
148	Response by Ho et al to Letter Regarding Article, â€œGenotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)â€. Circulation, 2019, 139, 1559-1560.	1.6	4
149	Rare X-linked storage heart diseases are tougher on men but not kind to women. International Journal of Cardiology, 2019, 286, 113-114.	1.7	0
150	CORRELATION OF ECHOCARDIOGRAPHIC FINDINGS WITH SYMPTOMS IN HYPERTROPHIC CARDIOMYOPATHY PATIENTS. Journal of the American College of Cardiology, 2019, 73, 990.	2.8	0
151	Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude. American Heart Journal, 2019, 214, 28-35.	2.7	1
152	Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. International Journal of Cardiology, 2019, 291, 77-82.	1.7	22
153	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 30-month results from the randomized phase 3 ATTRACT study. Molecular Genetics and Metabolism, 2019, 126, S53.	1.1	1
154	Comment on: Assessment of cardiac disease in MELAS requires comprehensive, prospective work-up. International Journal of Cardiology, 2019, 280, 162.	1.7	0
155	121â€...Re-evaluating the genetic contribution of monogenic dilated cardiomyopathy. , 2019, , .		1
156	Exercise testing in hypertrophic cardiomyopathy: A pathophysiological goldmine with protean clinical implications. International Journal of Cardiology, 2019, 274, 257-259.	1.7	1
157	Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). European Heart Journal, 2019, 40, 19-33.	2.2	288
158	No heart is an island: hypertrophic cardiomyopathy, diabetes, and the test of time. European Heart Journal, 2019, 40, 1678-1680.	2.2	4
159	Clinical profile and outcome of cardiac involvement in MELAS syndrome. International Journal of Cardiology, 2019, 276, 14-19.	1.7	21
160	Letter regarding the article â€˜Heart failure with preserved ejection fraction: from mechanisms to therapiesâ€™ by Lam and colleagues. European Heart Journal, 2019, 40, 703-704.	2.2	3
161	Acceptability, Feasibility and Preliminary Evaluation of a Novel, Personalised, Home-Based Physical Activity Intervention for Chronic Heart Failure (Active-at-Home-HF): a Pilot Study. Sports Medicine - Open, 2019, 5, 45.	3.1	11
162	Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events. JAMA Cardiology, 2018, 3, 520.	6.1	78

#	Article	IF	Citations
163	Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005820.	4.8	50
164	Late sodium current inhibitors to treat exerciseâ€induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. British Journal of Pharmacology, 2018, 175, 2635-2652.	5.4	49
165	Cardiac Resynchronization TherapyÂfor End-Stage Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2018, 71, 464-466.	2.8	25
166	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. Revista Portuguesa De Cardiologia, 2018, 37, 1-10.	0.5	38
167	Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004124.	3.9	103
168	Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: the importance of clinical context. European Heart Journal Cardiovascular Imaging, 2018, 19, 601-610.	1.2	45
169	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 1-10.	0.2	13
170	Clinical and Molecular Aspects of Cardiomyopathies. Heart Failure Clinics, 2018, 14, 161-178.	2.1	3
171	Common presentation of rare cardiac diseases: Arrhythmias. International Journal of Cardiology, 2018, 257, 351-357.	1.7	4
172	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation, 2018, 137, 1015-1023.	1.6	149
173	Contractile persistence in apical hypertrophic cardiomyopathy: Definitely too much of a good thing. International Journal of Cardiology, 2018, 251, 71-73.	1.7	2
174	Contemporary genetic testing in inherited cardiac disease. Journal of Cardiovascular Medicine, 2018, 19, 1-11.	1.5	48
175	Comparison of longâ€term outcome in anthracyclineâ€related versus idiopathic dilated cardiomyopathy: a single centre experience. European Journal of Heart Failure, 2018, 20, 898-906.	7.1	54
176	The Missense E258K-MyBP-C Mutation Increases the Energy Cost of Tension Generation in Both Ventricular and Atrial Tissue from HCM Patients. Biophysical Journal, 2018, 114, 314a.	0.5	0
177	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. Circulation, 2018, 138, 1387-1398.	1.6	468
178	Genetic testing in pediatric cardiomyopathies: Implications for diagnosis and management. Progress in Pediatric Cardiology, 2018, 51, 24-30.	0.4	3
179	Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy. International Journal of Cardiology, 2018, 273, 155-161.	1.7	17
180	Cardiomyopathies in children â€“ inherited heart muscle disease. Progress in Pediatric Cardiology, 2018, 51, 8-15.	0.4	1

#	Article	IF	Citations
181	Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e005191.	3.9	46
182	Channelopathies, cardiac hypertrophy, and the theory of light. European Heart Journal, 2018, 39, 2908-2910.	2.2	7
183	Impact of disease-causing mutations on inter-domain interactions in cMyBP-C: a steered molecular dynamics study. Journal of Biomolecular Structure and Dynamics, 2017, 35, 1916-1922.	3.5	14
184	Determinants of discrepancies between two-dimensional echocardiographic methods for assessment of maximal left atrial volume. European Heart Journal Cardiovascular Imaging, 2017, 18, 584-602.	1.2	4
185	Stress echo 2020: the international stress echo study in ischemic and non-ischemic heart disease. Cardiovascular Ultrasound, 2017, 15, 3.	1.6	82
186	Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2017, 231, 115-119.	1.7	30
187	Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (Î²-Myosin Heavy) Tj ETQq1 1 0.784314 rgBT /O Cardiovascular Imaging, 2017, 10, .	2.6	31
188	Atrial Remodeling in Hypertrophic Cardiomyopathy. Biophysical Journal, 2017, 112, 556a.	0.5	0
189	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. Journal of Medical Genetics, 2017, 54, 288-296.	3.2	262
190	Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .	3.9	76
191	Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-HeartÂ®). International Journal of Cardiology, 2017, 236, 249-252.	1.7	23
192	Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 866-875.	6.4	29
193	Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	42
194	B-lines with Lung Ultrasound: The Optimal Scan Technique atÂRest and During Stress. Ultrasound in Medicine and Biology, 2017, 43, 2558-2566.	1.5	50
195	Reply to: Is subcutaneous implantable cardioverter-defibrillator testing effective and safe for patients with hypertrophic cardiomyopathy?. International Journal of Cardiology, 2017, 246, 55.	1.7	0
196	Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models. Journal of the American Heart Association, 2017, 6, .	3.7	51
197	Role of Genetic Testing in Inherited Cardiovascular Disease. JAMA Cardiology, 2017, 2, 1153.	6.1	75
198	Intraoperative Diagnosis of Anderson-Fabry Disease in Patients With Obstructive Hypertrophic Cardiomyopathy Undergoing Surgical Myectomy. JAMA Cardiology, 2017, 2, 1147.	6.1	14

#	Article	IF	Citations
199	Role of Exercise Testing in HypertrophicÂCardiomyopathy. JACC: Cardiovascular Imaging, 2017, 10, 1374-1386.	5.3	68
200	Abrupt Onset of Refractory Heart Failure Associated With Light-Chain Amyloidosis in Hypertrophic Cardiomyopathy. JAMA Cardiology, 2017, 2, 94.	6.1	2
201	Grey zones in cardiomyopathies: defining boundaries between genetic and iatrogenic disease. Nature Reviews Cardiology, 2017, 14, 102-112.	13.7	18
202	Dissecting functional impairment in hypertrophic cardiomyopathy by dynamic assessment of diastolic reserve and outflow obstruction: A combined cardiopulmonary-echocardiographic study. International Journal of Cardiology, 2017, 227, 743-750.	1.7	11
203	Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2017, 6, .	3.7	48
204	Reversible Dilated Cardiomyopathy: Into the Thaumaturgy of the Heartâ€"Part 1. Neurology International, 2016, 6, 5861.	0.5	0
205	Reversible dilated cardiomyopathy: into the thaumaturgy of the heart - Part 2. Neurology International, 2016, 6, .	0.5	0
206	Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 118, 432-439.	1.6	45
207	Can anthropology improve our care of inherited cardiac arrhythmias? A modest proposal. Heart Rhythm, 2016, 13, 2395-2398.	0.7	0
208	Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. European Journal of Heart Failure, 2016, 18, 1106-1118.	7.1	101
209	Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2413-2422.	6.4	20
210	Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2016, 9, .	3.9	103
211	Electrophysiological correlates of word recognition memory process in patients with ischemic left ventricular dysfunction. Clinical Neurophysiology, 2016, 127, 3007-3013.	1.5	1
212	Multidimensional structure-function relationships in human Î²-cardiac myosin from population-scale genetic variation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6701-6706.	7.1	98
213	Prognostic role of stress echocardiography in hypertrophic cardiomyopathy: The International Stress Echo Registry. International Journal of Cardiology, 2016, 219, 331-338.	1.7	38
214	Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2016, 67, 1399-1409.	2.8	142
215	Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. American Journal of Cardiology, 2016, 117, 1651-1654.	1.6	95
216	Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 117, 1151-1159.	1.6	25

#	Article	IF	Citations
217	Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2016, 9, e002764.	3.9	51
218	Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy. Heart Rhythm, 2016, 13, 457-463.	0.7	46
219	Chagas disease as a cause of heart failure and ventricular arrhythmias in patients long removed from endemic areas. Journal of Cardiovascular Medicine, 2015, 16, 817-823.	1.5	13
220	Left Ventricular Apex Involvement in Hypertrophic Cardiomyopathy. Echocardiography, 2015, 32, 1575-1580.	0.9	3
221	Research priorities in sarcomeric cardiomyopathies. Cardiovascular Research, 2015, 105, 449-456.	3.8	48
222	Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?. Global Cardiology Science & Practice, 2015, 2015, 16.	0.4	9
223	INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on) Tj ETQq1 1 0.784314 rgBT /Ov 2015, 2015, 7.	0.4	11
224	Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. Cardiovascular Research, 2015, 105, 409-423.	3.8	66
225	An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2015, 8, 232-243.	2.4	14
226	Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2015, 116, 436-441.	1.6	62
227	Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2015, 8, 1014-1021.	3.9	67
228	Validation of pixel-wise parametric mapping of myocardial blood flow with 13NH3 PET in patients with hypertrophic cardiomyopathy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1581-1588.	6.4	12
229	Stress Echocardiography in Hypertrophic Cardiomyopathy. , 2015, , 551-568.		0
230	Microvascular ischaemia after cardiac arrest in a patient with hypertrophic cardiomyopathy. Global Cardiology Science & Practice, 2015, 2015, 51.	0.4	1
231	Reply. Journal of the American College of Cardiology, 2014, 64, 2562.	2.8	1
232	Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations. Journal of the American College of Cardiology, 2014, 64, 2589-2600.	2.8	118
233	MR Imaging in Hypertrophic Cardiomyopathy: From Magnet to Bedside. Radiology, 2014, 273, 329-348.	7.3	60
234	Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. Circulation, 2014, 130, 484-495.	1.6	783

#	Article	IF	Citations
235	Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2014, 64, 83-99.	2.8	541
236	Novel Î±-Actinin 2 Variant Associated With Familial Hypertrophic Cardiomyopathy and Juvenile Atrial Arrhythmias. Circulation: Cardiovascular Genetics, 2014, 7, 741-750.	5.1	74
237	Significance of Sarcomere Gene Mutations Analysis in the End-Stage Phase of Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2014, 114, 769-776.	1.6	76
238	Left Atrial Remodeling in Hypertrophic Cardiomyopathy and Susceptibility Markers for Atrial Fibrillation Identified by Cardiovascular Magnetic Resonance. American Journal of Cardiology, 2014, 113, 1394-1400.	1.6	95
239	Incremental prognostic value of multiparametric echocardiographic assessment for severe aortic stenosis. International Journal of Cardiology, 2014, 172, e356-e358.	1.7	2
240	Beta-Adrenergic Response in Human HCM Myocardium: Effects of Ranolazine. Biophysical Journal, 2014, 106, 347a.	0.5	0
241	Determinants of Abnormal Excitation-Contraction Coupling in Cardiomyocytes from Patients with Hypertrophic Cardiomyopathy. Biophysical Journal, 2013, 104, 106a.	0.5	0
242	Mutation E169K in Junctophilin-2 Causes Atrial Fibrillation Due to Impaired RyR2 Stabilization. Journal of the American College of Cardiology, 2013, 62, 2010-2019.	2.8	165
243	Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: A cardiac magnetic resonance study. International Journal of Cardiology, 2013, 167, 1038-1045.	1.7	38
244	Metabolomic fingerprint of heart failure in humans: A nuclear magnetic resonance spectroscopy analysis. International Journal of Cardiology, 2013, 168, e113-e115.	1.7	59
245	Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Outpatients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2013, 112, 1190-1196.	1.6	34
246	Early Results of Sarcomeric Gene Screening from the Egyptian National BA-HCM Program. Journal of Cardiovascular Translational Research, 2013, 6, 65-80.	2.4	31
247	Obesity and its Association to Phenotype and Clinical Course in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2013, 62, 449-457.	2.8	118
248	Improving Survival Rates of Patients With Idiopathic Dilated Cardiomyopathy in Tuscany Over 3 Decades. Circulation: Heart Failure, 2013, 6, 913-921.	3.9	50
249	Response to Letter Regarding Article, â€œLate Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathyâ€• Circulation, 2013, 128, e157.	1.6	11
250	Regulation of intracellular Na+in health and disease: pathophysiological mechanisms and implications for treatment. Global Cardiology Science & Practice, 2013, 2013, 30.	0.4	18
251	Hypertrophic cardiomyopathy: The need for randomized trials. Global Cardiology Science & Practice, 2013, 2013, 31.	0.4	10
252	Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy. Circulation, 2013, 127, 575-584.	1.6	347

#	Article	IF	Citations
253	Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Andersonâ€“Fabry disease. European Journal of Heart Failure, 2013, 15, 1363-1373.	7.1	49
254	Molecular Modeling of Disease Causing Mutations in Domain C1 of cMyBP-C. PLoS ONE, 2013, 8, e59206.	2.5	19
255	Dynamic assessment of 'valvular reserve capacity' in patients with rheumatic mitral stenosis. European Heart Journal Cardiovascular Imaging, 2012, 13, 476-482.	1.2	39
256	Patterns of Disease Progression in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2012, 5, 535-546.	3.9	258
257	Clinical and molecular classification of cardiomyopathies. Global Cardiology Science & Practice, 2012, 2012, 4.	0.4	14
258	Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy. Global Cardiology Science & Practice, 2012, 2012, 9.	0.4	13
259	Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis. BMJ Open, 2012, 2, e001267.	1.9	13
260	Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. European Heart Journal, 2012, 33, 1724-1733.	2.2	141
261	The coronary circulation and blood flow in left ventricular hypertrophy. Journal of Molecular and Cellular Cardiology, 2012, 52, 857-864.	1.9	144
262	Î² Blockers for Prevention of Exercise-Induced Left Ventricular Outflow Tract Obstruction in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2012, 110, 715-719.	1.6	71
263	Hemodynamic Progression and Outcome of Asymptomatic Aortic Stenosis in Primary Care. American Journal of Cardiology, 2012, 109, 718-723.	1.6	41
264	Distal extremity pain as a presenting feature of Fabry's disease. Arthritis Care and Research, 2011, 63, 390-395.	3.4	11
265	Microvascular Function Is Selectively Impaired in Patients With Hypertrophic Cardiomyopathy and Sarcomere Myofilament Gene Mutations. Journal of the American College of Cardiology, 2011, 58, 839-848.	2.8	138
266	Genetic testing for hypertrophic cardiomyopathy: ongoing voyage from exploration to clinical exploitation. Neurology International, 2011, 1, 3.	0.5	0
267	Mitral Valve Abnormalities Identified by Cardiovascular Magnetic Resonance Represent a Primary Phenotypic Expression of Hypertrophic Cardiomyopathy. Circulation, 2011, 124, 40-47.	1.6	343
268	Determinants of echocardiographic left atrial volume: implications for normalcy. European Journal of Echocardiography, 2011, 12, 826-833.	2.3	57
269	Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. European Heart Journal, 2011, 32, 1114-1120.	2.2	88
270	Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2010, 140, 1046-1052.	0.8	16

#	Article	IF	Citations
271	Spectrum and Clinical Significance of Systolic Function and Myocardial Fibrosis Assessed by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2010, 106, 261-267.	1.6	139
272	Timing and Significance of Exercise-Induced Left Ventricular Outflow Tract Pressure Gradients in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2010, 106, 1301-1306.	1.6	39
273	Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovascular Ultrasound, 2010, 8, 7.	1.6	62
274	Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	3.3	0
275	Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace, 2010, 12, 347-355.	1.7	127
276	Clinical Features and Outcome of Hypertrophic Cardiomyopathy Associated With Triple Sarcomere Protein Gene Mutations. Journal of the American College of Cardiology, 2010, 55, 1444-1453.	2.8	256
277	Myocardial bridging and sudden death in hypertrophic cardiomyopathy: Salome drops another veil. European Heart Journal, 2009, 30, 1549-1550.	2.2	13
278	Tunneled left anterior descending artery in a child with hypertrophic cardiomyopathy. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 134-139.	3.3	10
279	Looking for Hypertrophic Cardiomyopathy in the Community: Why Is It Important?. Journal of Cardiovascular Translational Research, 2009, 2, 392-397.	2.4	7
280	The Many Faces of Hypertrophic Cardiomyopathy: From Developmental Biology to Clinical Practice. Journal of Cardiovascular Translational Research, 2009, 2, 349-367.	2.4	65
281	Microvascular Dysfunction, Myocardial Ischemia, and Progression to Heart Failure in Patients with Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2009, 2, 452-461.	2.4	53
282	The Left Ventricular Outflow in Hypertrophic Cardiomyopathy: From Structure to Function. Journal of Cardiovascular Translational Research, 2009, 2, 510-517.	2.4	11
283	Hypertrophic Cardiomyopathy at 50. Journal of Cardiovascular Translational Research, 2009, 2, 339-340.	2.4	0
284	Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. Journal of Nuclear Cardiology, 2009, 16, 92-96.	2.1	25
285	The Case for Myocardial Ischemia in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2009, 54, 866-875.	2.8	254
286	Hypertrophic Cardiomyopathy Phenotype Revisited After 50 Years With Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology, 2009, 54, 220-228.	2.8	399
287	Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. Nature Reviews Cardiology, 2009, 6, 317-321.	13.7	72
288	The familial hypertrophic cardiomyopathyâ€associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. Journal of Physiology, 2008, 586, 3639-3644.	2.9	90

#	Article	IF	Citations
289	Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2008, 52, 559-566.	2.8	269
290	Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy. Mayo Clinic Proceedings, 2008, 83, 630-638.	3.0	198
291	Spatial Relationship Between Coronary Microvascular Dysfunction and Delayed Contrast Enhancement in Patients with Hypertrophic Cardiomyopathy. Journal of Nuclear Medicine, 2008, 49, 1090-1096.	5.0	68
292	Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy. Mayo Clinic Proceedings, 2008, 83, 630-638.	3.0	296
293	ECG-based screening: not only for athletes. European Heart Journal, 2007, 28, 1170-1170.	2.2	2
294	'End-stage' hypertrophic cardiomyopathy: from mystery to model. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 232-233.	3.3	32
295	Response to Letter Regarding Article, â€œHypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstructionâ€. Circulation, 2007, 115, .	1.6	1
296	Early discharge after acute myocardial infarction in the current clinical practice. Community data from the AMI-Florence Registry, Italy. International Journal of Cardiology, 2007, 114, 57-63.	1.7	18
297	Hypertrophic Cardiomyopathy in Anderson-Fabry Disease. Clinical Therapeutics, 2007, 29, S93-S94.	2.5	1
298	Left Ventricular Apical Ballooning Syndrome as a Novel Cause of Acute Mitral Regurgitation. Journal of the American College of Cardiology, 2007, 50, 647-649.	2.8	97
299	Surgical Myectomy Versus Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2007, 50, 831-834.	2.8	118
300	Usefulness and Safety of Transcatheter Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2007, 99, 1575-1581.	1.6	85
301	Relevance of Coronary Microvascular Flow Impairment to Long-Term Remodeling and Systolic Dysfunction in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2006, 47, 1043-1048.	2.8	208
302	Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction. Circulation, 2006, 114, 2232-2239.	1.6	830
303	Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction. American Heart Journal, 2006, 151, 1094-1100.	2.7	23
304	Association of Persistent Right Ventricular Dysfunction at Hospital Discharge After Acute Pulmonary Embolism With Recurrent Thromboembolic Events. Archives of Internal Medicine, 2006, 166, 2151.	3.8	101
305	A molecular screening strategy based on Î²-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. Journal of Cardiovascular Medicine, 2006, 7, 601-607.	1.5	64
306	Midventricular Obstruction and Clinical Decision-Making in Obstructive Hypertrophic Cardiomyopathy. Herz, 2006, 31, 871-876.	1.1	17

#	Article	IF	Citations
307	Usefulness of Bedside Testing for Brain Natriuretic Peptide to Identify Right Ventricular Dysfunction and Outcome in Normotensive Patients With Acute Pulmonary Embolism. American Journal of Cardiology, 2006, 97, 1386-1390.	1.6	133
308	Prognostic Significance of Left Atrial Size in Patients With Hypertrophic Cardiomyopathy (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	224
309	The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators?. European Heart Journal, 2006, 27, 1895-1897.	2.2	21
310	Minimally Invasive and Noninvasive Hemodynamic Monitoring of the Cardiovascular System: Available Options and Future Perspectives. Current Cardiology Reviews, 2006, 2, 37-39.	1.5	12
311	Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. European Journal of Heart Failure, 2005, 7, 566-571.	7.1	41
312	Hypertrophic cardiomyopathy in the community: why we should care. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 324-325.	3.3	12
313	The Italian registry for hypertrophic cardiomyopathy: A nationwide survey. American Heart Journal, 2005, 150, 947-954.	2.7	56
314	Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2005, 46, 470-476.	2.8	677
315	Gender-Related Differences in the Clinical Presentation and Outcome of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2005, 46, 480-487.	2.8	342
316	Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanisms and clinical consequences. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2004, 5, 572-80.	0.1	7
317	Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in tuscany. American Journal of Cardiology, 2003, 92, 1358-1362.	1.6	43
318	Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2003, 41, 315-321.	2.8	134
319	Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2003, 348, 295-303.	27.0	1,217
320	Coronary Microvascular Dysfunction and Prognosis in Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2003, 349, 1027-1035.	27.0	670
321	Determinants of treatment strategies and survival in acute myocardial infarction: a population-based study in the Florence district, Italy Results of the acute myocardial infarction Florence registry (AMI-Florence),,. European Heart Journal, 2003, 24, 1195-1203.	2.2	44
322	The epidemiologic evolution and present perception of hypertrophic cardiomyopathy. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2003, 4, 596-601.	0.1	2
323	New Concepts in Hypertrophic Cardiomyopathies. Circulation, 2002, 105, e188; author reply e188.	1.6	5
324	Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2002, 39, 301-307.	2.8	329

#	Article	IF	Citations
325	Effectiveness of a multidisciplinary chest pain unit for the assessment of coronary syndromes and risk stratification in the Florence area. American Heart Journal, 2002, 144, 630-635.	2.7	12
326	Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy. Current Cardiology Reports, 2001, 3, 141-146.	2.9	29
327	Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy. Circulation, 2001, 104, 2517-2524.	1.6	731
328	Short-Term Clinical Outcome of Patients With Acute Pulmonary Embolism, Normal Blood Pressure, and Echocardiographic Right Ventricular Dysfunction. Circulation, 2000, 101, 2817-2822.	1.6	785
329	Epidemiology of Hypertrophic Cardiomyopathyâ€“Related Death. Circulation, 2000, 102, 858-864.	1.6	727
330	Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 1999, 33, 2044-2051.	2.8	230
331	Utility of an integrated clinical, echocardiographic, and venous ultrasonographic approach for triage of patients with suspected pulmonary embolism. American Journal of Cardiology, 1998, 82, 1230-1235.	1.6	109
332	Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. American Heart Journal, 1998, 136, 972-981.	2.7	68
333	Syncope and ventricular arrhythmias in hypertrophic cardiomyopathy are not related to the derangement of coronary microvascular function. European Heart Journal, 1997, 18, 1946-1950.	2.2	7
334	Signal-averaged P-wave duration and risk of paroxysmal atrial fibrillation in hyperthyroidism. American Journal of Cardiology, 1996, 77, 266-269.	1.6	50
335	Effects of aging on neuroendocrine activation in subjects and patients in the presence and absence of heart failure with left ventricular systolic dysfunction. American Journal of Cardiology, 1996, 77, 1197-1201.	1.6	21
336	Hypertrophic cardiomyopathy in tuscany: Clinical course and outcome in an unselected regional population. Journal of the American College of Cardiology, 1995, 26, 1529-1536.	2.8	265
337	PARADOXICAL PROLONGATION OF QT INTERVAL DURING EXERCISE IN PATIENTS WITH HCM: CELLULAR MECHANISMS AND IMPLICATIONS FOR DIASTOLIC FUNCTION. European Heart Journal Open, 0, , .	2.3	1